Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and
ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.
The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or
IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).
The study was carried out retrospectively and included patients admitted with a first episode of ACS
between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP +
IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-
ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.
This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A – 53%, and 515 patients in subgroup B – 47%. Total cardiac mortality was 9.98%, different depending
on the groups and subgroups studied: HBP group total – 7%, subgroup A – 5.1%, significantly lower compared
to subgroup B – 9.4% (p = 0.05); IHD group total – 12.2%, subgroup A – 9.07%, significantly lower compared to
subgroup B – 15.8% (p = 0.05); HBP + IHD group total – 14.35%, subgroup A – 9.9%, significantly lower compared
to subgroup B – 18.8% (p = 0.05).
The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital
cardiac mortality among patients who develop a first-episode ACS.
Acute coronary syndrome, Cardiac mortality, Hypertension, Ischemic heart disease, Optimal cardio - vascular medication
Financial support: No grants or funding have been received for this study.
Conflict of interest:
None of the authors has financial interest related to this study to disclose.
September 18, 2017 Published Online:
October 14, 2017
Călin Pop George Cosbuc Street nr 31 Baia Mare, Romania email@example.com